|
SG11201706583PA
(en)
|
2015-02-19 |
2017-09-28 |
Compugen Ltd |
Anti-pvrig antibodies and methods of use
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
WO2017027422A1
(en)
|
2015-08-07 |
2017-02-16 |
Alexo Therapeutics Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
WO2017184553A1
(en)
*
|
2016-04-18 |
2017-10-26 |
Baylor College Of Medicine |
Cancer gene therapy targeting cd47
|
|
CN106084052B
(zh)
*
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
US12344669B2
(en)
|
2016-06-17 |
2025-07-01 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Anti-CD47 monoclonal antibody and use thereof
|
|
EP3481862A4
(en)
|
2016-07-06 |
2020-08-12 |
Celgene Corporation |
LOW IMMUNOGENIC ANTIBODIES AND USES THEREOF
|
|
CA3040440C
(en)
*
|
2016-07-15 |
2022-12-13 |
Korea Institute Of Science And Technology |
A novel nanocage and use thereof
|
|
SG11201901077RA
(en)
|
2016-08-17 |
2019-03-28 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
|
EP3411071A4
(en)
*
|
2016-10-20 |
2019-08-28 |
I-Mab |
NOVEL MONOCLONAL CD47 ANTIBODY AND USES THEREOF
|
|
US11779631B2
(en)
|
2016-11-03 |
2023-10-10 |
Pfizer Inc. |
CD47 blockade therapy by HDAC inhibitors
|
|
US11401329B2
(en)
*
|
2017-08-02 |
2022-08-02 |
Phanes Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
|
PT3587445T
(pt)
*
|
2017-08-10 |
2024-03-14 |
Grifols Diagnostic Solutions Inc |
Um marcador de oligomerização compreendendo uma região fc de imunoglobulina e um domínio poli-his
|
|
EP4435008A2
(en)
|
2017-08-18 |
2024-09-25 |
Centessa Pharmaceuticals (UK) Limited |
Binding agents
|
|
WO2019099852A1
(en)
*
|
2017-11-17 |
2019-05-23 |
University Of Massachusetts |
Humanized 2c7 monoclonal antibody directed against a neisseria gonorrhoeae lipooligosaccharide (los) epitope, for human use
|
|
TWI831759B
(zh)
|
2017-12-01 |
2024-02-11 |
美商思進公司 |
Cd47抗體及其用於治療癌症之用途
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
GB201804860D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
WO2019241732A1
(en)
|
2018-06-15 |
2019-12-19 |
Accurus Biosciences, Inc. |
Blocking antibodies against cd47 and methods of use thereof
|
|
CN109053882B
(zh)
*
|
2018-08-28 |
2019-08-23 |
东莞市朋志生物科技有限公司 |
一种ns1蛋白的结合蛋白以及应用
|
|
WO2020043188A1
(zh)
*
|
2018-08-31 |
2020-03-05 |
南京圣和药业股份有限公司 |
抗cd47抗体及其应用
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
SG11202108311RA
(en)
|
2019-02-26 |
2021-09-29 |
Janssen Biotech Inc |
Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
|
|
WO2020215012A1
(en)
*
|
2019-04-18 |
2020-10-22 |
Qlsf Biotherapeutics Inc. |
Antibodies that target human cd47
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
US11850248B2
(en)
|
2019-05-14 |
2023-12-26 |
Yuhan Corporation |
Therapies with 3rd generation EGFR tyrosine kinase inhibitors
|
|
PH12021552798A1
(en)
|
2019-05-14 |
2022-09-19 |
Janssen Biotech Inc |
Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
|
|
KR20220044904A
(ko)
|
2019-05-31 |
2022-04-12 |
알렉소 온콜로지 인크. |
면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
|
|
US20200400662A1
(en)
|
2019-06-07 |
2020-12-24 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
|
AU2020315598B2
(en)
|
2019-07-16 |
2024-12-12 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
|
KR20220097875A
(ko)
|
2019-09-03 |
2022-07-08 |
마이얼로이드 테라퓨틱스, 인크. |
게놈 통합을 위한 방법 및 조성물
|
|
KR102902719B1
(ko)
|
2019-10-18 |
2025-12-24 |
포티 세븐, 엘엘씨 |
골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
|
|
AU2020372522B2
(en)
|
2019-10-25 |
2024-08-15 |
WuXi Biologics Ireland Limited |
Novel anti-CD47 antibodies and uses thereof
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
CN114845710A
(zh)
|
2019-11-27 |
2022-08-02 |
Alx肿瘤生物技术公司 |
用于治疗癌症的组合疗法
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
EP4445902A3
(en)
|
2019-12-24 |
2024-12-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
JP7783182B2
(ja)
|
2020-02-12 |
2025-12-09 |
ヤンセン バイオテツク，インコーポレーテツド |
ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
|
|
CN117964757A
(zh)
|
2020-02-14 |
2024-05-03 |
吉利德科学公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
KR20230033647A
(ko)
|
2020-06-30 |
2023-03-08 |
멘두스 비.브이. |
난소암 백신에서 백혈병 유래 세포의 용도
|
|
EP4190813A4
(en)
*
|
2020-07-31 |
2025-02-12 |
Bio-Thera Solutions, Ltd. |
CD47 ANTIBODIES AND THEIR APPLICATION
|
|
JP2023550544A
(ja)
|
2020-11-03 |
2023-12-01 |
アールディスカバリー エルエルシー |
がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法
|
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス，インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|
|
US20220196651A1
(en)
|
2020-12-06 |
2022-06-23 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
US20240076412A1
(en)
*
|
2021-01-05 |
2024-03-07 |
National Institute Of Biological Sciences, Beijing |
A bispecific antibody targeting gpc3 and cd47
|
|
KR20230129481A
(ko)
*
|
2021-01-08 |
2023-09-08 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
Cd47과 특이적으로 결합하는 항체 및 그 항원 결합단편
|
|
WO2022190058A1
(en)
|
2021-03-12 |
2022-09-15 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
|
KR20240013094A
(ko)
|
2021-03-17 |
2024-01-30 |
마이얼로이드 테라퓨틱스, 인크. |
조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
BR112023023642A2
(pt)
|
2021-05-11 |
2024-01-30 |
Myeloid Therapeutics Inc |
Métodos e composições para integração genômica
|
|
BR112023022774A2
(pt)
|
2021-05-13 |
2024-01-02 |
Alx Oncology Inc |
Terapias de combinação para tratamento de câncer
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CN117881698A
(zh)
*
|
2021-06-30 |
2024-04-12 |
创新生物有限公司 |
对cd47具有特异性的人源化抗体及包含其的用于预防或治疗cd47相关疾病的药物组合物
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
AU2022376954B2
(en)
|
2021-10-29 |
2026-04-23 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
AU2022419982B2
(en)
|
2021-12-22 |
2026-04-16 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114371282B
(zh)
*
|
2021-12-30 |
2025-07-11 |
上海药明生物技术有限公司 |
一种评估抗原沉默效应对抗体药效影响的方法及其应用
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
EP4493554A1
(en)
|
2022-03-17 |
2025-01-22 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023183817A1
(en)
|
2022-03-24 |
2023-09-28 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
PE20250758A1
(es)
|
2022-07-01 |
2025-03-13 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
KR20250036855A
(ko)
|
2022-07-12 |
2025-03-14 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
JP2025540215A
(ja)
|
2022-12-09 |
2025-12-11 |
ファイザー・インク |
Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法
|
|
WO2024124107A2
(en)
|
2022-12-09 |
2024-06-13 |
Pfizer Inc. |
Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
|
|
CN118221812A
(zh)
*
|
2022-12-14 |
2024-06-21 |
上海迈石生物技术有限公司 |
一种靶向cd47的单克隆抗体及其应用
|
|
CN120225509A
(zh)
|
2022-12-22 |
2025-06-27 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
IL321674A
(en)
*
|
2022-12-29 |
2025-08-01 |
Shanghai Henlius Biotech Inc |
Anti-cd47 antibodies and methods of use
|
|
JP2026508945A
(ja)
|
2023-03-13 |
2026-03-13 |
ヤンセン バイオテツク，インコーポレーテツド |
二重特異性抗ＥＧＦＲ／ｃ－Ｍｅｔ抗体と抗ＰＤ－１抗体との併用療法
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2026089992A1
(en)
|
2024-10-21 |
2026-04-30 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|